Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

MicroRNAs in the Management of Heart Failure

Author(s): Aimilios Kalampogias*, Gerasimos Siasos*, Evangelos Oikonomou, Konstantinos Mourouzis, Evanthia Bletsa, Panagiota K. Stampouloglou, Efstratios Katsianos, Konstantinos Vlasis, Georgios Marinos, Georgios Charalambous, Manolis Vavouranakis and Dimitris Tousoulis

Volume 28, Issue 24, 2021

Published on: 18 February, 2021

Page: [4863 - 4876] Pages: 14

DOI: 10.2174/0929867328666210218181441

Price: $65


Background: In recent years much research has been devoted to the deployment of biomarkers in the field of heart failure.

Objectives: To study the potential of post-transcriptional regulation by microRNAs on the diagnosis, management and therapy of heart failure.

Methods: Literature search focuses on the role of microRNAs in heart failure.

Results: MicroRNAs are expressed and regulated in the course of the pathological manifestations of heart failure (HF). This wide and uncharted area of genetic imprints consisting of small non-coding RNA molecule is upregulated and released into the bloodstream from organs under certain conditions and or stress. The use of genetically based strategies for the management of HF has gained great interest in the field of biomedical science because they can be used as biomarkers providing information regarding cardiac status and function. They also appear as promising tools with therapeutic potential because of their ability to induce changes at the cellular level without creating alterations in the gene sequence. In addition, with the advances in genomic sequencing, quantification and synthesis in technologies of microRNAs identification as well as the growing knowledge of the biology of miRNAs and their involvement in HF, it is expected to favorably affect the prognosis of HF patients.

Conclusion: MicroRNAs are involved in the regulation of multibiological processes involved in the progress of heart failure. More studies are needed to achieve a clinical valuable implementation of microRNAs in the management of HF.

Keywords: Cardiac fibrosis, cardiomyocytes, cardiac remodeling, inflammation, cell therapy, regeneration.

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy